Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03641742 · ClinicalTrials.gov registry record
Families-At-risk for Interstitial Lung Disease Study
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 125
- Enrollment target
NCT03641742 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 125 participants.
The verdict
NCT03641742 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 125 participants
- Enrollment target
Study Summary
The interstitial lung diseases (ILDs) are a family of closely related lung conditions characterized by alveolar inflammation, injury, and fibrosis not due to infection or neoplasia. While previously considered to be rare, a recent nationwide study found that idiopathic pulmonary fibrosis (IPF), a fibrotic ILD with a median survival of only 3.8 years, affects nearly 0.5% of older adults in the U.S. While pirfenidone and nintedanib slow the progression of IPF, neither reverses fibrosis nor prevents progression of the disease,and no studies to date have tested interventions that prevent the development of fibrotic ILDs.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2023-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03641742
The ClinicalTrials.gov registry entry for NCT03641742 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03641742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03641742 about?
NCT03641742 is a clinical study titled "Families-At-risk for Interstitial Lung Disease Study". The interstitial lung diseases (ILDs) are a family of closely related lung conditions characterized by alveolar inflammation, injury, and fibrosis not due to infection or neoplasia. While previously considered to be rare, a recent nationwide study found that idiopathic pulmonary fibrosis (IPF), a fi...
What is the current status of trial NCT03641742?
This trial is currently completed. The enrollment target is 125 participants. The study started on 2018-01-15. Estimated completion is 2023-07-01.
Who is sponsoring clinical trial NCT03641742?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.